Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Open-label Phase II Study to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Trastuzumab-resistant HER2-overexpressing Metastatic Breast Cancer

NCT01985893 is registered in ClinicalTrials.gov with Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V. as lead sponsor.

NCT NCT01985893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01985893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Open-label Phase II Study to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Trastuzumab-resistant HER2-overexpressing Metastatic Breast Cancer
Lead sponsor
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2013
Completion date
March 31, 2015
Enrollment
0 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer